Macular Research Unit
-
Professor Robyn Guymer+61 3 99298360
Research Overview
The Macular Research unit at the Centre for Eye Research Australia (CERA) is a leading research team focusing on the most common cause of vision impairment in people aged over 50 years in Australia - Age-related macular degeneration (AMD). The group is headed by Professor Robyn Guymer, an internationally renowned medical retinal ophthalmologist and clinician. Prof Guymer's research is focused on finding novel ways to assess, monitor and treat this devastating eye disease. She also collaborates to investigate underlying mechanisms invovled in disease pathogenesis.
Staff
Professor Robyn Guymer, Group Leader, Professor
Assoc/Prof Chi Luu, Deputy Group Leader, Associate Professor -
Dr Penelope Allen - Senior Research Scientist
Dr Carla Abbott, Research Fellow
Dr Lauren Ayton, Senior Research Fellow
Dr Jia Jia Lek, Postdoctoral Research Fellow
Associate Professor Peter Keller
Miss Kate Brassington- Clincal trials Coordinator/ Orthoptist
Miss Emily Caruso - Clinical Trials Coordinator/Orthoptist
Miss Elizabeth Baglin - Clinical Trials Coordinator/Orthoptist
Mrs Pyrawy Sivarajah - Clinical Trials Orthoptist
Dr Galina Makeyeva - Research Assistant
Dr Khin Zaw Aung - Scientist
Dr Luba Robman - Senior Research Scientist
Ms Melinda Cain - Clinical Research Manager
Dr Amy Cohn - Senior Research Fellow
Ms Nicole Tindill - Database Manager
Ms Sue Griffin - Executive Assistant
Collaborators
Professor Darren Kelly, OccuRX
Associate Professor Erica Fletcher, University of Melbourne
Professor Steven Krillis, Department of Infections Disease, Immunology and Sexual Health, St George Hospital, NSW
Professor Ted Maddess, ARC Centre for Excellence in Vision Science, NSW
Martin Pera, Chair of Stem Cell Sciences at University of Melbourne
Associate Professor Fred Chen, Lions Eye Institute, W.A.
Dr Jenny Arnold, Marsden Eye Specialists
Professor Anthony Burkitt, Bionic Vision Australia
Professor Jim Wiley and Dr Ben Gu, The Florey Institute of Neuroscience and Mental Health
Professor Graham Giles and Dallas English, Cancer Council of Victoria.
Associate Professor Mark Gillies, University of Sydney.
Professor John Hopper, Centre for Genetic Epidemiology, University of Melbourne.
Victor Previn, Ellex Australia, Adelaide, South Australia.
Professor Rob Shepperd, Peter Blamey, Bionic Ear Institute.
Drs Gregg Suaning and Nigell Lovell, School of Biomedical Engineering, UNSW
Professors Steven Prawer, John Morley and M Ibbitson – Bionic Vision Australia
Associate Professor Algis Vingrys, Department of Optometry and Visual Sciences. University of Melbourne
Emeritus Professor Alan Bird, Moorfields Eye Hospital. UK
Dr David Birch, Retina Foundation of the Southwest, USA
Professor Emily Chew, National Eye Institute, Maryland, USA
Professor Usha Chakravarthy, The Queens University, Belfast
Dr Karl Csaky, Retina Foundation of the Southwest
Frederick Ferris, National Eye Institute, Bethesda, Maryland, USA
Professor Martin Friedlander, The Scripps Research Institute, California, USA
Professor Gregory Hageman, University of Iowa. USA
Professor Frank Holz, University of Bonn, Germany
Philip Luthert, UCL Institute of Ophthalmology
Professor Phil Rosenfeld, Bascom Palmer Eye Institute, Miami, USA
Funding
Current NHMRC Support
2016-2020NHMRC Research Fellowship (GNT1103013) $828,300.00 Age-related macular degeneration: A cause and a cure . CIA Robyn Guymer
2016-2013NHMRC Development Grant (APP1113654) $366,300 Novel ways of treating angiogenesis in the eye. CID Robyn Guymer
2015-2017NHMRC Project Grant (APP10832358) $1,182,255.25. Safety and Efficacy of a Surgically Implanted Suprachoroidal Retinal Prosthesis ("Bionic Eye") – AI – Robyn Guymer
2015-2017NHMRC Project Grant (APP 1084081) $547,179.70. Novel functional imaging for age-related macular degeneration – CIB Robyn Guymer
2014-2016NHMRC Project Grant (APP1060323) $630,558. Oxidation of complement proteins and AMD – CIA Prof Steven Krilis; AI Robyn Guymer
2014-2016NHMRC: Project Grant (APP 1063458) - $552,562. Novel functional testing for macular degeneration. CIA Prof Ted Maddess; AI Prof Robyn Guymer
2014-2016NHMRC: Project Grant (APP1061419) $659,890. The role of purines in age related macular degeneration. CIA Assoc Prof Erica Fletcher CIC Robyn Guymer.
2014-2017NHMRC: Project Grant (APP1059369) 552,562. Uncovering the pathogenesis of age-related macular degeneration using induced pluripotent stem cells. CIA Alice Pebay CIB Robyn Guymer
2013-2016NHMRC: Project Grant (APP10511625): $991,797.06 Project Title: Low dose aspirin and age-related macular degeneration: randomised controlled trial. CIA Prof John McNeil (Monash University) CIB Robyn Guymer
2016Macular Disease Foundation: $200,000
Research Outcomes
1.Wu ZC, Ayton LN, Luu CD, Baird PN, Guymer RH. Reticular Pseudodrusen in Intermediate Age-Related Macular Degeneration: Prevalence, Detection, Clinical, Environmental, and Genetic Associations. IOVS. 2016;57(3):1310-6.
2.Wu Z, Guymer RH, Finger RP. Low luminance deficit and night vision symptoms in intermediate age-related macular degeneration. Brit J Ophthalmol. 2016;100(3):395-8.
3.Qi M, Abdelatti M, Krilis M, Madigan MC, Weaver J, Guymer RH, et al. Do Beta 2-Glycoprotein I Disulfide Bonds Protect the Human Retina in the Setting of Age-Related Macular Degeneration? Antioxidants & Redox Signalling. 2016;24(1):32-8.
4.McGuinness MB, Karahalios A, Simpson JA, Guymer RH, Robman LD, Hodge AM, et al. Past physical activity and age-related macular degeneration: the Melbourne Collaborative Cohort Study. Brit J Ophthalmol. 2016 January 19, 2016.
5.Greferath U, Guymer RH, Vessey KA, Brassington K, author) FEGRijf. Correlation of histological features with in-vivo imaging of reticular pseudodrusen. Ophthalmology. 2016;Accepted for publication 2/2/2016.
6.Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134.
7.Finger RP, Chong E, McGuinness MB, Robman LD, Aung KZ, Giles G, et al. Reticular Pseudodrusen and Their Association with Age-Related Macular Degeneration: The Melbourne Collaborative Cohort Study. Ophthalmology. 2016;123(3):599-608.
8.Arnold JA MC, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmology. 2016;16(31).
9.Wu ZC, Ayton LN, Luu CD, Guymer RH. Longitudinal Changes in Microperimetry and Low Luminance Visual Acuity In Age-related Macular Degeneration Jama Ophthalmology. 2015;133(4):442-8. PubMed PMID: doi:10.1001/jamaophthalmol.2014.5963.
10.Wu Z, Luu CD, Ayton LN, Goh JKS, Lucci LM, Hubbard WC, et al. Fundus Autofluorescence Characteristics of Nascent Geographic Atrophy in Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2015;56(3):1546-52.
11.Wu Z, Jung CJ, Ayton LN, Luu CD, Guymer RH. Test–Retest Repeatability of Microperimetry at the Border of Deep ScotomasTest–Retest Repeatability of Microperimetry. Invest Ophth Vis Sci. 2015;56(4):2606-11.
12.Wu Z, Guymer RH, Jung CJ, Goh JK, Ayton LN, Luu CD, et al. Measurement of Retinal Sensitivity on Tablet Devices in Age-Related Macular Degeneration. Translational vision science & technology. 2015;4(3).
13.Wu Z, Ayton LN, Luu CD, Guymer RH. Microperimetry of Nascent Geographic Atrophy in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015;56(1):115-21.
14.Wu Z, Ayton L, Makeyeva G, Guymer RH, Luu CD. Impact of Reticular Pseudodrusen on Microperimetry and Multifocal Electroretinography in Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015;56(3):2100-6.
15.Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH. Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina (Philadelphia, Pa). 2015.
16.Tao LW, Wu Z, Guymer RH, Luu CD. Ellipsoid zone on optical coherence tomography: a review. Clin Experiment Ophthalmol. 2015 Nov 21. PubMed PMID: 26590363. Epub 2015/11/22. Eng.
17.Stavert B, McGuinness MB, Harper CA, Guymer RH, Finger RP. Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2015 Mar 19;133(6):647-52. PubMed PMID: 25789577.
18.Robman LD, Islam FMA, Chong EWT, Adams MKM, Simpson JA, Aung KZ, et al. Age-Related Macular Degeneration in Ethnically Diverse Australia: Melbourne Collaborative Cohort Study. Ophthal Epidemiol. 2015;22(2):75-84. PubMed PMID: 25777306.
19.Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, et al. Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Ophthalmology. 2015;122(12):2497-503.
20.Razavi H, Arnold J, Guymer R. To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration? Clinical & Experimental Ophthalmology. 2015;43(8):707-10.
21.Osthoff M, Dean MM, Baird PN, Richardson AJ, Daniell M, Guymer RH, et al. Association Study of Mannose-Binding Lectin Levels and Genetic Variants in Lectin Pathway Proteins with Susceptibility to Age-Related Macular Degeneration: A Case-Control Study. PloS one. 2015;10(7):e0134107.
22.O'Hare F, Bentley SA, Wu Z, Guymer RH, Luu CD, Ayton LN. Charles Bonnet Syndrome in Advanced Retinitis Pigmentosa. Ophthalmology. 2015 Apr 11;122(9):1951-3.
23.Nguyen TT, Guymer R. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Rev Clin Pharmacol. 2015 Sep;8(5):541-8.
24.Jobling AI, Guymer RH, Vessey KA, Greferath U, Mills SA, Brassington K, et al. Nanosecond laser therapy reverses pathological and molecular changes in age-related macular degeneration without retinal damage. FASEBJ. 2015;29(2):696-710.
25.Guymer R, Cipriani T, Rittenhouse K, Lim L, Robman L, Li W, et al. Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology. 2015 2015/08/01;253(8):1347-54. English.
26.Gisbert R, Mones J, Korobelnik JF, Wolf S, Guymer RH, Goldstein M, et al. Scheduled versus Pro Re Nata (PRN) Dosing in the VIEW Trials Ophthalmology. 2015 9 January 2015;122(12):2497-503.
27.Gillies MC, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, et al. Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab. Ophthalmology. 2015 3//;122(3):589-94.e1.
28.Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2015;122(9):1837-45.
29.Fenwick EK, O'Hare F, Deverell L, Ayton LN, Luu CD, McSweeney S, et al. Rasch Analysis of the Independent Mobility Questionnaire. Optometry and vision science: official publication of the American Academy of Optometry. 2015;93(2):181-7.
30.Chong EW, Wang YY, Robman LD, Aung KZ, Makeyeva GA, Giles GG, et al. Age Related Macular Degeneration and Total Hip Replacement Due to Osteoarthritis or Fracture: Melbourne Collaborative Cohort Study. Plos One. 2015 Sep 10;10(9).
31.Chong EW, Amirul Islam FM, Robman LD, Aung KZ, Richardson AJ, Baird PN, et al. Age-Related Macular Degeneration Phenotypes Associated with Mutually Exclusive Homozygous Risk Variants in Cfh and Htra1 Genes. Retina. 2015 Jan 26;35(5):989-98.
32.Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, et al. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2015 Mar;99(3):359-64.
33.Barthelmes D, Campain AE, Arnold JJ, McAllister I, Simpson JM, Hunyor AP, et al. Effects of Switching from Ranibizumab to Aflibercept on Visual Outcome, Lesion Activity and Treatment Intensity in Eyes with Neovascular Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2015;56(7):4589-.
34.Barthelmes D, Arnold JJ, Campain A, Simpson JM, Guymer R, Hunyor A, et al. Two Year Outcomes of "Treat And Extend" Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2015 15 December 2014;122(6):1212-9.
35.Barnes NM, Scott AF, Stacey A, McCarthy C, Feng D, Petoe MA, et al. Enhancing object contrast using augmented depth improves mobility in patients implanted with a retinal prosthesis. Invest Ophth Vis Sci. 2015;56(7):755-.
36.Leow S, Luu CD, Nizam MH, Mok P, Ruhaslizan R, Wong HS, et al. Safety and efficacy of human Wharton's Jelly-derived mesenchymal stem cells therapy for retinal degeneration. Plos One. 2015;10(6):e0128973.
37.Leung RT, Nayagam DA, Williams RA, Allen PJ, Salinas-La Rosa CM, Luu CD, et al. Safety and efficacy of explanting or replacing suprachoroidal electrode arrays in a feline model. Clin Experiment Ophthalmol. 2015 Apr;43(3):247-58.
38.Man RE, Sasongko MB, Xie J, Kawasaki R, Best WJ, Noonan JE, et al. Associations of retinal oximetry in persons with diabetes. Clin Experiment Ophthalmol. 2015 Mar;43(2):124-31. PubMed PMID: 25041320. Epub 2014/07/22. eng.
39.Fox K, Meffin H, Burns O, Abbott CJ, Allen PJ, Opie NL, et al. Development of a Magnetic Attachment Method for Bionic Eye Applications. Artif Organs. 2015.
Research Publications
Chapters
1.Ayton LN, Guymer RH, Allen PJ, Luu CD. Bionic Eyes: Vision Restoration Through Electronic or Photovoltaic Stimulation. In: Pebay A, editor. Regenerative Biology of the Eye: Humana Press; 2014. p. 257-74.
Peer reviewed journal articles
1.Wu ZC, Ayton LN, Luu CD, Baird PN, Guymer RH. Reticular Pseudodrusen in Intermediate Age-Related Macular Degeneration: Prevalence, Detection, Clinical, Environmental, and Genetic Associations. IOVS. 2016;57(3):1310-6.
2.Wu Z, Guymer RH, Finger RP. Low luminance deficit and night vision symptoms in intermediate age-related macular degeneration. Brit J Ophthalmol. 2016;100(3):395-8.
3.Qi M, Abdelatti M, Krilis M, Madigan MC, Weaver J, Guymer RH, et al. Do Beta 2-Glycoprotein I Disulfide Bonds Protect the Human Retina in the Setting of Age-Related Macular Degeneration? Antioxidants & Redox Signalling. 2016;24(1):32-8.
4.McGuinness MB, Karahalios A, Simpson JA, Guymer RH, Robman LD, Hodge AM, et al. Past physical activity and age-related macular degeneration: the Melbourne Collaborative Cohort Study. Brit J Ophthalmol. 2016 January 19, 2016.
5.Greferath U, Guymer RH, Vessey KA, Brassington K, author) FEGRijf. Correlation of histological features with in-vivo imaging of reticular pseudodrusen. Ophthalmology. 2016;Accepted for publication 2/2/2016.
6.Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48(2):134.
7.Finger RP, Chong E, McGuinness MB, Robman LD, Aung KZ, Giles G, et al. Reticular Pseudodrusen and Their Association with Age-Related Macular Degeneration: The Melbourne Collaborative Cohort Study. Ophthalmology. 2016;123(3):599-608.
8.Arnold JA MC, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmology. 2016;16(31).
9.Aplin FP, Vessey KA, Luu CD, Guymer RH, Shepherd RK, Fletcher EL. Retinal changes in an ATP-induced model of retinal degeneration. Frontiers in Neuroanatomy. 2016 2016-April-29;10. English.
10.Wu ZC, Ayton LN, Luu CD, Guymer RH. Longitudinal Changes in Microperimetry and Low Luminance Visual Acuity In Age-related Macular Degeneration Jama Ophthalmology. 2015;133(4):442-448
11.Wu Z, Luu CD, Ayton LN, Guymer RH. Re: Wu et al.: Optical coherence tomographyLdefined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology. 2015;Author Reply(121):2415-22.
12.Wu Z, Luu CD, Ayton LN, Goh JKS, Lucci LM, Hubbard WC,Hageman J, Hageman G, Guymer RH. Fundus Autofluorescence Characteristics of Nascent Geographic Atrophy in Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2015;56(3):1546-52.
13.Wu Z, Jung CJ, Ayton LN, Luu CD, Guymer RH. Test-retest repeatability of microperimetry at the border of deep scotomas. Invest Ophthalmol Vis Sci. 2015;56(4):2606-11.
13.Wu Z, Guymer RH, Jung CJ, Goh JK, Ayton LN, Luu CD, et al. Measurement of Retinal Sensitivity on Tablet Devices in Age-Related Macular Degeneration. Translational vision science & technology. 2015;4(3).
14.Wu Z, Guymer RH, Finger RP. Low luminance deficit and night vision symptoms in intermediate age-related macular degeneration. Brit J Ophthalmol. 2015,100(3):395-398
15.Wu Z, Ayton LN, Luu CD, Guymer RH. Microperimetry of Nascent Geographic Atrophy in Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015;56(1):115-21.
16.Wu Z, Ayton LN, Makeyeva G, Guymer RH, Luu CD. Impact of Reticular Pseudodrusen on Microperimetry and Multifocal Electroretinography in Intermediate Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2015;56(3):2100-6..
17.Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH. Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina (Philadelphia, Pa). 2015. Epub Dec 11, 2015
18.Stavert B, McGuinness MB, Harper CA, Guymer RH, Finger RP. Cardiovascular Adverse Effects of Phenylephrine Eyedrops: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2015 133 (6) 647-52
19.Robman LD, Islam FMA, Chong EWT, Adams MKM, Simpson JA, Aung KZ, Makeyeva GA, Hopper JL, English DR, Giles GG, Baird PN, Guymer RH. Age-Related Macular Degeneration in Ethnically Diverse Australia: Melbourne Collaborative Cohort Study. Ophthal Epidemiol. 2015;22(2):75-84..
20.Richard G, Monés J, Wolf S, Korobelnik JF, Guymer R, Goldstein M, et al. Scheduled versus Pro Re Nata Dosing in the VIEW Trials. Ophthalmology. 2015;122(12):2497-503
21.Razavi H, Arnold J, Guymer R. To dry or not too dry: should we be more tolerant of stable subretinal fluid in patients receiving anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration? Clinical & Experimental Ophthalmology. 2015;43(8):707-10.
22.Osthoff M, Dean MM, Baird PN, Richardson AJ, Daniell M, Guymer RH, et al. Association Study of Mannose-Binding Lectin Levels and Genetic Variants in Lectin Pathway Proteins with Susceptibility to Age-Related Macular Degeneration: A Case-Control Study. PloS one. 2015;10(7):e0134107.
23.O'Hare F, Bentley SA, Wu Z, Guymer RH, Luu CD, Ayton LN. Charles Bonnet Syndrome in Advanced Retinitis Pigmentosa. Ophthalmology. 2015 ;122(9);1951-3
24.Nguyen TT, Guymer R. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Rev Clin Pharmacol. 2015 Sep;8(5):541-8.
25.Jobling AI, Guymer RH, Vessey KA, Greferath U, Mills SA, Brassington K, et al. Nanosecond laser therapy reverses pathological and molecular changes in age-related macular degeneration without retinal damage. FASEBJ. 2015;29(2):696-710.
26.Guymer R, Cipriani T, Rittenhouse KD, Lim L, Robman LD, Li W, et al. Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology. 2015:253(8)1347-1354..
27.Gisbert R, Mones J, Korobelnik JF, Wolf S, Guymer RH, Goldstein M, et al. Scheduled versus Pro Re Nata (PRN) Dosing in the VIEW Trials Ophthalmology. 2015,122(12)2497-503Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study. Ophthalmology. 2015;122(9):1837-45.
28.Gillies MC, Campain A, Walton R, Simpson JM, Arnold JJ, Guymer RH, et al. Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab. Ophthalmology. 2015;122(3):589-94.e1.
29.Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, … Guymer RH et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2015;48(2):134.
30.Finger RP, Chong E, McGuinness MB, Robman LD, Aung KZ, Giles G,Baird PN, Guymer RH. Reticular Pseudodrusen and Their Association with Age-Related Macular Degeneration: The Melbourne Collaborative Cohort Study. Ophthalmology. 2015;123(3):599-608
31.Fenwick EK, O'Hare F, Deverell L, Ayton LN, Luu CD, McSweeney S, Bentley SA, Guymer RH, Finger RP.. Rasch Analysis of the Independent Mobility Questionnaire. Optometry and vision science: official publication of the American Academy of Optometry. 2015;93(2):181-7.
32.Chong EW, Wang YY, Robman LD, Aung KZ, Makeyeva GA, Giles GG, Graves S, Cicuttini FM, Guymer RH. Age Related Macular Degeneration and Total Hip Replacement Due to Osteoarthritis or Fracture: Melbourne Collaborative Cohort Study. Plos One. 2015 Sep 10;10(9).
33.Chong EW, Amirul Islam FM, Robman LD, Aung KZ, Richardson AJ, Baird PN, Guymer RH. Age-Related Macular Degeneration Phenotypes Associated with Mutually Exclusive Homozygous Risk Variants in Cfh and Htra1 Genes. Retina. 2015 35(5):989-98
34.Barthelmes D, Walton R, Campain AE, Simpson JM, Arnold JJ, McAllister IL, Guymer RH, et al. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol. 2015 Mar;99(3):359-64.
35.Barthelmes D, Arnold JJ, Campain A, Simpson JM, Guymer R, Hunyor A, et al. Two Year Outcomes of "Treat And Extend" Intravitreal Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2015;122 (16): 1212-1219
36.Barthelmes D, Campain AE, Arnold JJ, McAllister I, Simpson JM, Hunyor AP, Guymer RH et al. Effects of Switching from Ranibizumab to Aflibercept on Visual Outcome, Lesion Activity and Treatment Intensity in Eyes with Neovascular Age-Related Macular Degeneration. Invest Ophth Vis Sci. 2015;56(7):4589-4589.
37.Barnes NM, Scott AF, Stacey A, McCarthy C, Feng D, Petoe MA, Ayton LN, Dengate R, Guymer RH, Walker J. Enhancing object contrast using augmented depth improves mobility in patients implanted with a retinal prosthesis. Invest Ophth Vis Sci. 2015;56(7):755-755.
Peer reviewed journal articles as member of study group
1.Slater KD, Sinclair NC, Nelson TS, Blamey PJ, McDermott HJ, Bionic Vision Australia Consortium, et al. neuroBi: A highly configurable neurostimulator for a retinal prosthesis and other applications. IEEE Journal of Translation Engineering in Health and Medicine. 2015;Accepted for publication 3/7/2015